An "uncontested market" in the neoadjuvant setting potentially awaits Sun’s partnered melanoma asset Nidlegy, while competition heats up for products like Cequa in the US. Scrip pieces together management commentary and analysts’ outlook on some of the key specialty therapies that India’s top-ranked drug maker is building out.

Sun Pharma sees all time high market share and prescription trends in the US for key specialty products and remains upbeat on the prospects of deuruxolitinib for alopecia areata. The company also isn’t ruling out a potential comeback, at least not yet, for a higher dose version of the JAK1/2 inhibitor.

Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.

The Swiss-Italian biotech firm’s two lead assets for cancer are expecting pivotal readouts next year, prompting it to consider partnering strategies and further substantiating its targeted R&D approach.